ClinicalTrials.gg
Active, not recruitingNCT06242652Updated Oct 23, 2024

A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS)

A Phase 2 interventional study of 608 Dose A and 608 Dose B in Ankylosing Spondylitis, sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-23.

Sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (part of 3SBio Inc.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 8 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 76 studies in Spondylitis, Ankylosing with a site in China — 19 open to participants now, 22 under way, 4 of them phase 3. Spondylitis, Ankylosing · China.

Planned enrollment
19th of 62
250 · median 150
Started
2024
with 2 others
Phase 2
11 of 76
none open now
Primary completion
2025-02
later than 2 of 21 live
Registered
55th of 76
by date
Lead sponsor
3 of 76
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Among the 76 studies in Spondylitis, Ankylosing with a site in China, this one is the 19th largest by planned enrollment of the 62 interventional ones that give a count, is one of 3 that started in 2024, is one of 11 in phase 2, reaches primary completion later than 2 of the 21 other live ones, and was the 55th registered.

Spondylitis, Ankylosing

533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

19 of the 76 studies in Spondylitis, Ankylosing with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Spondylitis, Ankylosing with a site in China, or all of them as a file.
02

Study summary

This study will evaluate the effect and safety of 608 in patients with AS.

Read the detailed description

The purpose of this study is to demonstrate the clinical efficacy, safety and tolerability of 608 compared to placebo and positive drug in patients with AS.

03

Conditions studied

  • Ankylosing Spondylitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female and male patients at least 18 years of age at the time of screening.
  2. Participant with a clinical diagnosis of ankylosing spondylitis (AS) and meeting the modified New York criteria for AS.
  3. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score >= 4 and a Patient's Assessment of Total Back Pain score >= 4 based on a 0 - 10 numeric rating scale (NRS) at the Screening and Baseline visits.
  4. If entering the study on concomitant NSAIDs for AS, participant must be on stable dose(s) for at least 2 weeks prior to the Baseline visit.

Exclusion criteria

Exclusion Criteria:

  1. Patients with other uncontrolled active inflammatory diseases.
  2. Clinical laboratory tests and other tests that reveal abnormalities with clinical significance
  3. Patients who have active , or infections as determined by positive results at Screening.
  4. History of cancer.
  5. Known or suspected history of .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    608 Dose A

    608 Dose A subcutaneous (SC) injection.

    Drug: 608 Dose A

  • Experimental
    608 Dose B

    608 Dose B subcutaneous (SC) injection.

    Drug: 608 Dose B

  • Experimental
    608 Dose C

    608 Dose C subcutaneous (SC) injection.

    Drug: 608 Dose C

  • Active comparator
    Positive control group

    Adalimumab subcutaneous (SC) injection.

    Drug: Adalimumab

  • Placebo comparator
    Placebo

    Placebo subcutaneous (SC) injection.

    Drug: Placebo

Interventions

  • Drug608 Dose A

    608 subcutaneous (SC) injection.

    Also known as: SSGJ-608 Dose A

  • Drug608 Dose B

    608 subcutaneous (SC) injection.

    Also known as: SSGJ-608 Dose B

  • Drug608 Dose C

    608 subcutaneous (SC) injection.

    Also known as: SSGJ-608 Dose C

  • Adalimumab subcutaneous (SC) injection.

    Also known as: Humira

  • DrugPlacebo

    Placebo subcutaneous (SC) injection.

06

What researchers measure

Primary outcomes

  1. The Percentage of Participants Who Achieved an Assessment of Spondylo Arthritis International Society (ASAS) 20 Response.

    Assessment of Spondylo Arthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a NRS; 2. Patient's assessment of back pain, measured on a NRS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by NRS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by NRS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). ASAS 20 response is defined as an improvement of ≥20% and ≥1 unit on a scale of 10 in at least three of the four main domains and no worsening of ≥20% and ≥1 unit on a scale of 10 in the remaining domain. A higher score on the NRS signifies higher severity.

    Time frame: Week 16.

Secondary outcomes

  1. The Percentage of Participants Who Achieved an Assessment of Spondylo Arthritis International Society (ASAS) 40 Response.

    Assessment of Spondylo Arthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a NRS; 2. Patient's assessment of back pain, measured on a NRS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by NRS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by NRS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain. A higher score on the NRS signifies higher severity.

    Time frame: Week 16.

Other outcomes

  1. 608 Concentration in Serum.

    The concentration of 608 in Serum.

    Time frame: Up to 24 Weeks.

07

Study locations

1 site
  • Site 01
    Beijing, Beijing 100730, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Feb 2025, 11 months after the start.

Of 22 phase 2 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2024
First posted
Feb 5, 2024
StartActual
Mar 19, 2024
Primary completionEst.
Feb 27, 2025
CompletionEst.
Jun 15, 2025
Last update
Oct 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06242652
Responsible party
Sponsor
First posted
Feb 5, 2024
Start date
Mar 19, 2024
Primary completion
Feb 27, 2025 (estimated)
Completion
Jun 15, 2025 (estimated)
Last update
Oct 23, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion